| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Skin Neoplasms | 28 | 2023 | 404 | 3.840 |
Why?
|
| Melanoma | 16 | 2021 | 329 | 2.090 |
Why?
|
| Skin Diseases | 9 | 2021 | 76 | 1.510 |
Why?
|
| Sweet Syndrome | 3 | 2021 | 8 | 1.470 |
Why?
|
| Skin | 14 | 2021 | 357 | 1.230 |
Why?
|
| Biomarkers, Tumor | 11 | 2018 | 461 | 1.140 |
Why?
|
| Carcinoma | 3 | 2016 | 115 | 0.980 |
Why?
|
| Biopsy | 16 | 2023 | 411 | 0.930 |
Why?
|
| Scleroderma, Localized | 3 | 2023 | 10 | 0.920 |
Why?
|
| Sweat Gland Neoplasms | 3 | 2023 | 20 | 0.830 |
Why?
|
| Immunohistochemistry | 15 | 2018 | 847 | 0.810 |
Why?
|
| Hair Follicle | 1 | 2021 | 29 | 0.740 |
Why?
|
| Salivary Glands, Minor | 1 | 2020 | 3 | 0.720 |
Why?
|
| Sjogren's Syndrome | 1 | 2020 | 24 | 0.700 |
Why?
|
| Carcinoma, Squamous Cell | 4 | 2021 | 237 | 0.680 |
Why?
|
| Diagnosis, Differential | 17 | 2019 | 937 | 0.670 |
Why?
|
| Middle Aged | 39 | 2021 | 16317 | 0.650 |
Why?
|
| Humans | 83 | 2023 | 59360 | 0.650 |
Why?
|
| Leukemia, Myeloid, Acute | 3 | 2018 | 167 | 0.590 |
Why?
|
| Leukemia-Lymphoma, Adult T-Cell | 1 | 2017 | 10 | 0.580 |
Why?
|
| Carcinoma, Basal Cell | 2 | 2021 | 63 | 0.580 |
Why?
|
| Keratinocytes | 2 | 2015 | 63 | 0.560 |
Why?
|
| Immunocompromised Host | 2 | 2017 | 100 | 0.560 |
Why?
|
| Facial Dermatoses | 2 | 2014 | 10 | 0.540 |
Why?
|
| Breast Diseases | 1 | 2017 | 39 | 0.540 |
Why?
|
| Eyelid Neoplasms | 1 | 2016 | 9 | 0.530 |
Why?
|
| Mucins | 1 | 2016 | 25 | 0.530 |
Why?
|
| Carcinosarcoma | 1 | 2016 | 6 | 0.520 |
Why?
|
| Uterine Neoplasms | 1 | 2016 | 29 | 0.510 |
Why?
|
| Amyloidosis, Familial | 1 | 2015 | 2 | 0.510 |
Why?
|
| Melanocytes | 3 | 2019 | 78 | 0.510 |
Why?
|
| Skin Diseases, Genetic | 1 | 2015 | 6 | 0.500 |
Why?
|
| Male | 43 | 2021 | 27739 | 0.500 |
Why?
|
| Proto-Oncogene Proteins B-raf | 6 | 2018 | 53 | 0.460 |
Why?
|
| Female | 42 | 2023 | 30705 | 0.450 |
Why?
|
| Skin Diseases, Vesiculobullous | 1 | 2014 | 5 | 0.450 |
Why?
|
| Neoplasms, Multiple Primary | 2 | 2013 | 29 | 0.440 |
Why?
|
| Mohs Surgery | 2 | 2012 | 52 | 0.440 |
Why?
|
| Central Nervous System Neoplasms | 1 | 2013 | 38 | 0.430 |
Why?
|
| Hair Diseases | 1 | 2013 | 6 | 0.420 |
Why?
|
| Langerhans Cell Sarcoma | 2 | 2013 | 2 | 0.410 |
Why?
|
| Pemphigus, Benign Familial | 1 | 2012 | 1 | 0.400 |
Why?
|
| Acute Generalized Exanthematous Pustulosis | 1 | 2012 | 1 | 0.400 |
Why?
|
| Aged, 80 and over | 18 | 2021 | 5128 | 0.400 |
Why?
|
| HIV Infections | 2 | 2017 | 913 | 0.400 |
Why?
|
| Pregnancy Complications | 1 | 2017 | 364 | 0.390 |
Why?
|
| Adenocarcinoma, Mucinous | 1 | 2011 | 30 | 0.360 |
Why?
|
| Aged | 24 | 2021 | 13416 | 0.360 |
Why?
|
| Dermatitis | 3 | 2023 | 27 | 0.340 |
Why?
|
| Drug Eruptions | 2 | 2009 | 14 | 0.340 |
Why?
|
| Lupus Erythematosus, Cutaneous | 2 | 2021 | 13 | 0.330 |
Why?
|
| DNA Mutational Analysis | 5 | 2018 | 188 | 0.330 |
Why?
|
| Neoplasm Invasiveness | 5 | 2019 | 250 | 0.320 |
Why?
|
| Antibodies, Monoclonal | 5 | 2009 | 839 | 0.320 |
Why?
|
| Bone Morphogenetic Proteins | 2 | 2021 | 61 | 0.320 |
Why?
|
| Adenoma, Pleomorphic | 2 | 2023 | 8 | 0.310 |
Why?
|
| Langerhans Cells | 1 | 2008 | 11 | 0.300 |
Why?
|
| Telomerase | 2 | 2018 | 31 | 0.280 |
Why?
|
| Umbilicus | 1 | 2007 | 16 | 0.280 |
Why?
|
| Fibrosis | 3 | 2023 | 153 | 0.280 |
Why?
|
| B7-H1 Antigen | 2 | 2018 | 54 | 0.280 |
Why?
|
| Proto-Oncogene Proteins | 3 | 2017 | 318 | 0.280 |
Why?
|
| Acne Keloid | 1 | 2006 | 1 | 0.270 |
Why?
|
| Griseofulvin | 1 | 2006 | 1 | 0.270 |
Why?
|
| Tinea Capitis | 1 | 2006 | 1 | 0.270 |
Why?
|
| Skin Diseases, Vascular | 1 | 2006 | 3 | 0.270 |
Why?
|
| Plasminogen Activator Inhibitor 1 | 1 | 2006 | 15 | 0.270 |
Why?
|
| Kidney Failure, Chronic | 2 | 2009 | 206 | 0.270 |
Why?
|
| Leukemia, Prolymphocytic | 1 | 2006 | 1 | 0.270 |
Why?
|
| Leukemia, Prolymphocytic, T-Cell | 1 | 2006 | 2 | 0.270 |
Why?
|
| Tumor Necrosis Factor-alpha | 5 | 2009 | 588 | 0.270 |
Why?
|
| Biopsy, Needle | 3 | 2021 | 132 | 0.260 |
Why?
|
| MicroRNAs | 3 | 2019 | 616 | 0.260 |
Why?
|
| Neoplasm Recurrence, Local | 4 | 2018 | 300 | 0.260 |
Why?
|
| Thalidomide | 1 | 2006 | 32 | 0.250 |
Why?
|
| Adult | 23 | 2021 | 15669 | 0.250 |
Why?
|
| Neurilemmoma | 1 | 2005 | 11 | 0.250 |
Why?
|
| Face | 2 | 2021 | 33 | 0.250 |
Why?
|
| Leprosy | 1 | 2005 | 7 | 0.250 |
Why?
|
| Tissue Plasminogen Activator | 1 | 2006 | 125 | 0.250 |
Why?
|
| Predictive Value of Tests | 4 | 2016 | 1025 | 0.240 |
Why?
|
| Exanthema | 1 | 2005 | 26 | 0.240 |
Why?
|
| Repressor Proteins | 2 | 2018 | 332 | 0.240 |
Why?
|
| Immunoglobulin G | 2 | 2009 | 446 | 0.240 |
Why?
|
| Psoriasis | 3 | 2012 | 50 | 0.230 |
Why?
|
| Administration, Oral | 2 | 2021 | 356 | 0.230 |
Why?
|
| Adenocarcinoma | 1 | 2007 | 323 | 0.230 |
Why?
|
| Reoperation | 3 | 2023 | 272 | 0.230 |
Why?
|
| Mutation | 6 | 2019 | 2456 | 0.230 |
Why?
|
| Adaptor Proteins, Signal Transducing | 2 | 2019 | 411 | 0.230 |
Why?
|
| Histiocytes | 2 | 2018 | 5 | 0.230 |
Why?
|
| Prostatic Neoplasms | 1 | 2007 | 339 | 0.220 |
Why?
|
| Polyps | 1 | 2023 | 4 | 0.220 |
Why?
|
| Bleomycin | 2 | 2023 | 32 | 0.220 |
Why?
|
| Fibroma | 1 | 2023 | 12 | 0.220 |
Why?
|
| Promoter Regions, Genetic | 1 | 2006 | 651 | 0.220 |
Why?
|
| Colorectal Neoplasms | 2 | 2017 | 263 | 0.210 |
Why?
|
| Granuloma | 2 | 2014 | 41 | 0.210 |
Why?
|
| Drug Hypersensitivity | 2 | 2016 | 28 | 0.200 |
Why?
|
| Fatal Outcome | 2 | 2016 | 116 | 0.200 |
Why?
|
| Chin | 1 | 2021 | 4 | 0.190 |
Why?
|
| Treatment Outcome | 4 | 2021 | 5284 | 0.190 |
Why?
|
| Lupus Erythematosus, Discoid | 1 | 2021 | 8 | 0.190 |
Why?
|
| Carcinoma in Situ | 1 | 2021 | 32 | 0.180 |
Why?
|
| Neck | 1 | 2021 | 46 | 0.180 |
Why?
|
| Prednisone | 1 | 2021 | 85 | 0.180 |
Why?
|
| Lupus Nephritis | 1 | 2021 | 33 | 0.180 |
Why?
|
| Aftercare | 1 | 2021 | 69 | 0.180 |
Why?
|
| Artificial Intelligence | 1 | 2023 | 155 | 0.180 |
Why?
|
| Neural Crest | 1 | 2021 | 26 | 0.180 |
Why?
|
| Nose Deformities, Acquired | 1 | 2020 | 1 | 0.180 |
Why?
|
| Signal Transduction | 5 | 2021 | 2902 | 0.180 |
Why?
|
| Proto-Oncogene Proteins c-myc | 2 | 2015 | 96 | 0.180 |
Why?
|
| Rhinoplasty | 1 | 2020 | 10 | 0.170 |
Why?
|
| GTP Phosphohydrolases | 2 | 2018 | 59 | 0.170 |
Why?
|
| Nose | 1 | 2020 | 28 | 0.170 |
Why?
|
| Software | 1 | 2023 | 367 | 0.170 |
Why?
|
| Staining and Labeling | 1 | 2020 | 124 | 0.170 |
Why?
|
| Xanthomatosis | 1 | 2019 | 8 | 0.170 |
Why?
|
| Uveal Neoplasms | 1 | 2019 | 52 | 0.170 |
Why?
|
| Janus Kinase Inhibitors | 1 | 2020 | 17 | 0.170 |
Why?
|
| Glucocorticoids | 1 | 2021 | 179 | 0.160 |
Why?
|
| Dermatologic Agents | 2 | 2009 | 20 | 0.160 |
Why?
|
| Chemokine CXCL10 | 2 | 2023 | 56 | 0.160 |
Why?
|
| Nasopharyngeal Neoplasms | 1 | 2019 | 8 | 0.160 |
Why?
|
| Cell Line, Tumor | 6 | 2019 | 1370 | 0.160 |
Why?
|
| Ki-67 Antigen | 2 | 2016 | 34 | 0.160 |
Why?
|
| Keratosis, Seborrheic | 1 | 2018 | 1 | 0.150 |
Why?
|
| HIV-1 | 2 | 2017 | 692 | 0.150 |
Why?
|
| Epidermolysis Bullosa Dystrophica | 2 | 2019 | 14 | 0.150 |
Why?
|
| Adolescent | 8 | 2023 | 5824 | 0.150 |
Why?
|
| Subcutaneous Tissue | 1 | 2018 | 14 | 0.150 |
Why?
|
| Fas Ligand Protein | 1 | 2018 | 39 | 0.150 |
Why?
|
| Young Adult | 4 | 2017 | 4267 | 0.150 |
Why?
|
| Fluorescent Antibody Technique, Direct | 1 | 2018 | 9 | 0.150 |
Why?
|
| Phenotype | 6 | 2018 | 1137 | 0.150 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 1 | 2018 | 98 | 0.150 |
Why?
|
| Growth Differentiation Factor 6 | 1 | 2017 | 3 | 0.150 |
Why?
|
| Receptors, Nerve Growth Factor | 2 | 2015 | 7 | 0.150 |
Why?
|
| CD8-Positive T-Lymphocytes | 2 | 2017 | 648 | 0.140 |
Why?
|
| Trans-Activators | 1 | 2019 | 300 | 0.140 |
Why?
|
| Gene Expression Profiling | 1 | 2021 | 718 | 0.140 |
Why?
|
| Disease Progression | 3 | 2019 | 1122 | 0.140 |
Why?
|
| Follow-Up Studies | 6 | 2011 | 2337 | 0.140 |
Why?
|
| Toll-Like Receptor 7 | 1 | 2018 | 95 | 0.140 |
Why?
|
| Hyperpigmentation | 1 | 2017 | 6 | 0.140 |
Why?
|
| Lichen Planus | 1 | 2017 | 9 | 0.140 |
Why?
|
| Kidney Transplantation | 2 | 2011 | 313 | 0.140 |
Why?
|
| Coinfection | 1 | 2017 | 44 | 0.140 |
Why?
|
| Cell Cycle Proteins | 1 | 2019 | 384 | 0.140 |
Why?
|
| Mixed Function Oxygenases | 1 | 2017 | 19 | 0.140 |
Why?
|
| Leg Ulcer | 2 | 2006 | 4 | 0.140 |
Why?
|
| Toll-Like Receptor 9 | 1 | 2018 | 202 | 0.140 |
Why?
|
| Neoplasm Regression, Spontaneous | 1 | 2016 | 4 | 0.140 |
Why?
|
| Lymphocytes, Tumor-Infiltrating | 1 | 2017 | 35 | 0.140 |
Why?
|
| Carcinoma, Merkel Cell | 1 | 2016 | 8 | 0.140 |
Why?
|
| Erythema Nodosum | 1 | 2016 | 3 | 0.130 |
Why?
|
| Hypercholesterolemia | 1 | 2017 | 68 | 0.130 |
Why?
|
| Azathioprine | 1 | 2016 | 27 | 0.130 |
Why?
|
| Neurofibromin 1 | 1 | 2016 | 11 | 0.130 |
Why?
|
| Loss of Heterozygosity | 1 | 2016 | 24 | 0.130 |
Why?
|
| Testicular Neoplasms | 1 | 2016 | 32 | 0.130 |
Why?
|
| MafG Transcription Factor | 1 | 2016 | 5 | 0.130 |
Why?
|
| Neoplasm Proteins | 1 | 2017 | 277 | 0.130 |
Why?
|
| Warts | 2 | 2019 | 6 | 0.130 |
Why?
|
| Neoplasms, Radiation-Induced | 2 | 2015 | 27 | 0.130 |
Why?
|
| Foot | 1 | 2015 | 41 | 0.120 |
Why?
|
| Cell Differentiation | 2 | 2017 | 1304 | 0.120 |
Why?
|
| Head and Neck Neoplasms | 1 | 2016 | 148 | 0.120 |
Why?
|
| Vascular Endothelial Growth Factor Receptor-3 | 1 | 2015 | 21 | 0.120 |
Why?
|
| Proto-Oncogene Proteins c-ret | 4 | 2016 | 8 | 0.120 |
Why?
|
| Infliximab | 4 | 2009 | 49 | 0.120 |
Why?
|
| Membrane Proteins | 2 | 2018 | 850 | 0.120 |
Why?
|
| RNA-Binding Proteins | 1 | 2018 | 386 | 0.120 |
Why?
|
| Gene Expression Regulation, Neoplastic | 4 | 2021 | 475 | 0.120 |
Why?
|
| Hemangiosarcoma | 1 | 2015 | 23 | 0.120 |
Why?
|
| Necrosis | 2 | 2013 | 140 | 0.120 |
Why?
|
| Peripheral Nerves | 1 | 2015 | 30 | 0.120 |
Why?
|
| Membrane Glycoproteins | 1 | 2018 | 661 | 0.120 |
Why?
|
| Mice | 8 | 2023 | 10292 | 0.110 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2016 | 289 | 0.110 |
Why?
|
| Child, Preschool | 3 | 2016 | 1782 | 0.110 |
Why?
|
| Sebaceous Gland Neoplasms | 1 | 2014 | 10 | 0.110 |
Why?
|
| CD4-Positive T-Lymphocytes | 2 | 2010 | 620 | 0.110 |
Why?
|
| Sequence Analysis, DNA | 2 | 2015 | 394 | 0.110 |
Why?
|
| Amniotic Band Syndrome | 1 | 2014 | 4 | 0.110 |
Why?
|
| Animals | 11 | 2023 | 19651 | 0.110 |
Why?
|
| Ultrasonography | 1 | 2016 | 459 | 0.110 |
Why?
|
| DNA Mismatch Repair | 1 | 2014 | 31 | 0.110 |
Why?
|
| ras Proteins | 1 | 2014 | 77 | 0.110 |
Why?
|
| Postoperative Complications | 1 | 2020 | 1202 | 0.110 |
Why?
|
| Immunosuppressive Agents | 2 | 2016 | 365 | 0.110 |
Why?
|
| Receptors, Notch | 1 | 2014 | 101 | 0.110 |
Why?
|
| Gene Silencing | 1 | 2016 | 378 | 0.110 |
Why?
|
| Adalimumab | 3 | 2009 | 30 | 0.100 |
Why?
|
| Apocrine Glands | 1 | 2012 | 2 | 0.100 |
Why?
|
| Eccrine Glands | 1 | 2012 | 3 | 0.100 |
Why?
|
| Cell Transformation, Neoplastic | 1 | 2014 | 193 | 0.100 |
Why?
|
| Polymerase Chain Reaction | 3 | 2016 | 495 | 0.100 |
Why?
|
| Epigenesis, Genetic | 1 | 2016 | 357 | 0.100 |
Why?
|
| Lichen Nitidus | 1 | 2012 | 2 | 0.100 |
Why?
|
| Radiodermatitis | 1 | 2012 | 10 | 0.100 |
Why?
|
| Blister | 1 | 2012 | 17 | 0.100 |
Why?
|
| Retrospective Studies | 2 | 2021 | 6071 | 0.100 |
Why?
|
| Cell Proliferation | 4 | 2019 | 942 | 0.100 |
Why?
|
| Ultraviolet Therapy | 1 | 2012 | 14 | 0.100 |
Why?
|
| Eyebrows | 1 | 2012 | 1 | 0.100 |
Why?
|
| Neoplasms, Complex and Mixed | 1 | 2011 | 2 | 0.100 |
Why?
|
| Lymphangioma | 1 | 2011 | 3 | 0.100 |
Why?
|
| Interleukin-1 | 1 | 2012 | 157 | 0.100 |
Why?
|
| Genotype | 3 | 2011 | 617 | 0.100 |
Why?
|
| Transcription Factors | 1 | 2019 | 1471 | 0.100 |
Why?
|
| Facial Neoplasms | 1 | 2011 | 7 | 0.090 |
Why?
|
| Antigens, CD1 | 2 | 2008 | 42 | 0.090 |
Why?
|
| Vitiligo | 1 | 2014 | 123 | 0.090 |
Why?
|
| Antibodies, Monoclonal, Humanized | 3 | 2009 | 219 | 0.090 |
Why?
|
| In Situ Hybridization, Fluorescence | 2 | 2012 | 152 | 0.090 |
Why?
|
| Neoplasm Metastasis | 1 | 2011 | 188 | 0.090 |
Why?
|
| Cell Nucleus | 2 | 2018 | 608 | 0.090 |
Why?
|
| Etanercept | 2 | 2009 | 32 | 0.080 |
Why?
|
| Lymphopenia | 1 | 2010 | 35 | 0.080 |
Why?
|
| Receptors, Tumor Necrosis Factor | 2 | 2009 | 62 | 0.080 |
Why?
|
| Antigens, CD | 2 | 2013 | 343 | 0.080 |
Why?
|
| Pregnancy | 1 | 2017 | 2202 | 0.080 |
Why?
|
| Polymorphism, Genetic | 3 | 2016 | 185 | 0.080 |
Why?
|
| Biological Therapy | 1 | 2009 | 16 | 0.080 |
Why?
|
| Chemokine CXCL9 | 2 | 2023 | 24 | 0.080 |
Why?
|
| Ligands | 2 | 2023 | 411 | 0.080 |
Why?
|
| Nuclear Proteins | 1 | 2014 | 750 | 0.080 |
Why?
|
| CD4 Antigens | 1 | 2010 | 148 | 0.080 |
Why?
|
| Keloid | 1 | 2009 | 3 | 0.080 |
Why?
|
| Receptors, CXCR3 | 2 | 2023 | 35 | 0.080 |
Why?
|
| Arthritis, Psoriatic | 2 | 2007 | 33 | 0.080 |
Why?
|
| Child | 3 | 2016 | 4174 | 0.080 |
Why?
|
| Obesity | 1 | 2017 | 1166 | 0.080 |
Why?
|
| Breast Neoplasms | 2 | 2015 | 1118 | 0.080 |
Why?
|
| Nephrogenic Fibrosing Dermopathy | 1 | 2009 | 22 | 0.080 |
Why?
|
| Hypersensitivity, Immediate | 1 | 2008 | 9 | 0.080 |
Why?
|
| Trichosporon | 1 | 2008 | 1 | 0.080 |
Why?
|
| Epidermis | 1 | 2008 | 35 | 0.080 |
Why?
|
| Up-Regulation | 2 | 2023 | 365 | 0.080 |
Why?
|
| Histoplasma | 1 | 2008 | 15 | 0.080 |
Why?
|
| Dermatomycoses | 1 | 2008 | 13 | 0.080 |
Why?
|
| Histoplasmosis | 1 | 2008 | 23 | 0.080 |
Why?
|
| S100 Proteins | 1 | 2008 | 19 | 0.070 |
Why?
|
| Recombinant Fusion Proteins | 2 | 2009 | 490 | 0.070 |
Why?
|
| Papillomavirus Infections | 1 | 2010 | 120 | 0.070 |
Why?
|
| Immunoenzyme Techniques | 1 | 2008 | 107 | 0.070 |
Why?
|
| Tattooing | 1 | 2008 | 3 | 0.070 |
Why?
|
| Scalp | 1 | 2008 | 29 | 0.070 |
Why?
|
| Collagen Diseases | 1 | 2008 | 4 | 0.070 |
Why?
|
| AIDS-Related Opportunistic Infections | 1 | 2008 | 68 | 0.070 |
Why?
|
| Cytoplasmic Granules | 1 | 2008 | 51 | 0.070 |
Why?
|
| Pyoderma Gangrenosum | 1 | 2008 | 6 | 0.070 |
Why?
|
| Leukemia, Promyelocytic, Acute | 1 | 2007 | 18 | 0.070 |
Why?
|
| Protein Kinase C | 1 | 2008 | 98 | 0.070 |
Why?
|
| Urachal Cyst | 1 | 2007 | 2 | 0.070 |
Why?
|
| Impetigo | 1 | 2007 | 3 | 0.070 |
Why?
|
| Anti-Inflammatory Agents | 1 | 2009 | 164 | 0.070 |
Why?
|
| Infusions, Intravenous | 1 | 2008 | 164 | 0.070 |
Why?
|
| Vasculitis, Leukocytoclastic, Cutaneous | 1 | 2006 | 1 | 0.070 |
Why?
|
| Methimazole | 1 | 2006 | 8 | 0.070 |
Why?
|
| Graves Disease | 1 | 2006 | 15 | 0.070 |
Why?
|
| Osteomyelitis | 1 | 2007 | 23 | 0.070 |
Why?
|
| CD52 Antigen | 1 | 2006 | 4 | 0.070 |
Why?
|
| Nerve Tissue Proteins | 3 | 2015 | 418 | 0.070 |
Why?
|
| Antithyroid Agents | 1 | 2006 | 18 | 0.070 |
Why?
|
| Caustics | 1 | 2006 | 1 | 0.070 |
Why?
|
| Chemexfoliation | 1 | 2006 | 1 | 0.070 |
Why?
|
| Trichloroacetic Acid | 1 | 2006 | 3 | 0.070 |
Why?
|
| Acantholysis | 1 | 2006 | 5 | 0.070 |
Why?
|
| Cytogenetic Analysis | 1 | 2006 | 23 | 0.070 |
Why?
|
| Antibodies, Antineutrophil Cytoplasmic | 1 | 2006 | 36 | 0.070 |
Why?
|
| Gene Amplification | 1 | 2006 | 23 | 0.070 |
Why?
|
| Gene Rearrangement | 1 | 2006 | 38 | 0.070 |
Why?
|
| HEK293 Cells | 2 | 2019 | 587 | 0.070 |
Why?
|
| Mice, Inbred BALB C | 2 | 2018 | 868 | 0.060 |
Why?
|
| Aneuploidy | 1 | 2006 | 40 | 0.060 |
Why?
|
| Epithelioid Cells | 1 | 2005 | 4 | 0.060 |
Why?
|
| Philippines | 1 | 2005 | 5 | 0.060 |
Why?
|
| Heparin | 1 | 2006 | 111 | 0.060 |
Why?
|
| Antigens, Neoplasm | 1 | 2006 | 133 | 0.060 |
Why?
|
| Receptors, Antigen, T-Cell, alpha-beta | 1 | 2006 | 119 | 0.060 |
Why?
|
| Nevus, Pigmented | 1 | 2005 | 19 | 0.060 |
Why?
|
| Mice, Nude | 2 | 2017 | 258 | 0.060 |
Why?
|
| Drug Therapy, Combination | 1 | 2006 | 452 | 0.060 |
Why?
|
| Glycoproteins | 1 | 2006 | 186 | 0.060 |
Why?
|
| Microscopy, Electron, Transmission | 1 | 2005 | 133 | 0.060 |
Why?
|
| Progesterone | 1 | 2006 | 158 | 0.060 |
Why?
|
| Gene Rearrangement, gamma-Chain T-Cell Antigen Receptor | 1 | 2004 | 2 | 0.060 |
Why?
|
| Polymorphism, Single-Stranded Conformational | 1 | 2004 | 16 | 0.060 |
Why?
|
| Lymphocyte Activation | 2 | 2018 | 743 | 0.060 |
Why?
|
| Lymphoma, T-Cell, Cutaneous | 1 | 2004 | 8 | 0.060 |
Why?
|
| Precancerous Conditions | 1 | 2004 | 70 | 0.060 |
Why?
|
| Autoimmune Diseases | 1 | 2006 | 220 | 0.060 |
Why?
|
| Genetic Predisposition to Disease | 2 | 2018 | 676 | 0.050 |
Why?
|
| Cross-Sectional Studies | 2 | 2023 | 2373 | 0.050 |
Why?
|
| Antirheumatic Agents | 1 | 2006 | 214 | 0.050 |
Why?
|
| Severity of Illness Index | 4 | 2009 | 1479 | 0.050 |
Why?
|
| Disease Models, Animal | 3 | 2018 | 2050 | 0.050 |
Why?
|
| DNA, Viral | 2 | 2016 | 223 | 0.050 |
Why?
|
| Models, Immunological | 1 | 2002 | 85 | 0.050 |
Why?
|
| Lung Transplantation | 1 | 2002 | 67 | 0.050 |
Why?
|
| Anticoagulants | 1 | 2006 | 477 | 0.050 |
Why?
|
| Vasculitis | 1 | 2002 | 50 | 0.050 |
Why?
|
| Time Factors | 3 | 2016 | 3617 | 0.050 |
Why?
|
| Arthritis, Rheumatoid | 1 | 2006 | 322 | 0.050 |
Why?
|
| Lower Extremity | 1 | 2023 | 152 | 0.050 |
Why?
|
| DNA | 1 | 2006 | 806 | 0.050 |
Why?
|
| Receptors, Antigen, T-Cell, gamma-delta | 2 | 2017 | 70 | 0.050 |
Why?
|
| Autoantibodies | 2 | 2018 | 172 | 0.050 |
Why?
|
| Administration, Topical | 1 | 2021 | 47 | 0.050 |
Why?
|
| Fluorouracil | 1 | 2021 | 55 | 0.050 |
Why?
|
| Gene Ontology | 1 | 2021 | 38 | 0.050 |
Why?
|
| Graft Rejection | 1 | 2002 | 289 | 0.050 |
Why?
|
| Fibroblasts | 1 | 2023 | 377 | 0.050 |
Why?
|
| Multiple Myeloma | 1 | 2006 | 325 | 0.040 |
Why?
|
| Chemokines | 1 | 2021 | 93 | 0.040 |
Why?
|
| Pharyngeal Muscles | 1 | 2000 | 1 | 0.040 |
Why?
|
| Transcutaneous Electric Nerve Stimulation | 1 | 2000 | 3 | 0.040 |
Why?
|
| Embryo, Nonmammalian | 1 | 2021 | 169 | 0.040 |
Why?
|
| Iatrogenic Disease | 1 | 2020 | 58 | 0.040 |
Why?
|
| Models, Animal | 1 | 2021 | 221 | 0.040 |
Why?
|
| Cadaver | 1 | 2020 | 110 | 0.040 |
Why?
|
| Animals, Genetically Modified | 1 | 2021 | 280 | 0.040 |
Why?
|
| Keratitis | 1 | 2019 | 9 | 0.040 |
Why?
|
| Piperidines | 1 | 2020 | 55 | 0.040 |
Why?
|
| Mice, Inbred C57BL | 2 | 2020 | 3231 | 0.040 |
Why?
|
| Sleep Apnea, Obstructive | 1 | 2000 | 54 | 0.040 |
Why?
|
| Pyrimidines | 1 | 2020 | 131 | 0.040 |
Why?
|
| Sarcoma, Synovial | 1 | 2018 | 6 | 0.040 |
Why?
|
| Immune System | 1 | 2020 | 129 | 0.040 |
Why?
|
| Co-Repressor Proteins | 1 | 2018 | 22 | 0.040 |
Why?
|
| Mitogen-Activated Protein Kinases | 1 | 2019 | 205 | 0.040 |
Why?
|
| Tissue Fixation | 1 | 2018 | 21 | 0.040 |
Why?
|
| Paraffin Embedding | 1 | 2018 | 16 | 0.040 |
Why?
|
| Ovalbumin | 1 | 2018 | 116 | 0.040 |
Why?
|
| Formaldehyde | 1 | 2018 | 32 | 0.040 |
Why?
|
| Zebrafish | 1 | 2021 | 326 | 0.040 |
Why?
|
| Microphthalmia-Associated Transcription Factor | 1 | 2017 | 13 | 0.040 |
Why?
|
| Peptide Hydrolases | 1 | 2018 | 78 | 0.040 |
Why?
|
| Th1 Cells | 1 | 2018 | 174 | 0.040 |
Why?
|
| Gene Expression Regulation, Developmental | 1 | 2021 | 619 | 0.030 |
Why?
|
| Natural Killer T-Cells | 1 | 2017 | 27 | 0.030 |
Why?
|
| Jaw | 1 | 2016 | 4 | 0.030 |
Why?
|
| Merkel cell polyomavirus | 1 | 2016 | 5 | 0.030 |
Why?
|
| Cell Movement | 1 | 2019 | 429 | 0.030 |
Why?
|
| Genes, p16 | 1 | 2016 | 6 | 0.030 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 1 | 2019 | 327 | 0.030 |
Why?
|
| Sentinel Lymph Node Biopsy | 1 | 2016 | 38 | 0.030 |
Why?
|
| Interferon Type I | 1 | 2018 | 169 | 0.030 |
Why?
|
| Xenograft Model Antitumor Assays | 1 | 2017 | 178 | 0.030 |
Why?
|
| Withholding Treatment | 1 | 2016 | 40 | 0.030 |
Why?
|
| Inflammation | 1 | 2023 | 1099 | 0.030 |
Why?
|
| Tumor Microenvironment | 1 | 2017 | 140 | 0.030 |
Why?
|
| Carcinogenesis | 1 | 2017 | 118 | 0.030 |
Why?
|
| Cell Lineage | 1 | 2017 | 259 | 0.030 |
Why?
|
| Hematopoietic Stem Cells | 1 | 2017 | 276 | 0.030 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2016 | 396 | 0.030 |
Why?
|
| B-Lymphocytes | 1 | 2018 | 550 | 0.030 |
Why?
|
| Oxidative Stress | 1 | 2017 | 279 | 0.030 |
Why?
|
| Chi-Square Distribution | 1 | 2016 | 409 | 0.030 |
Why?
|
| Survival Analysis | 1 | 2016 | 555 | 0.030 |
Why?
|
| Crohn Disease | 1 | 2016 | 106 | 0.030 |
Why?
|
| Protein-Tyrosine Kinases | 1 | 2015 | 119 | 0.030 |
Why?
|
| MutL Protein Homolog 1 | 1 | 2014 | 24 | 0.030 |
Why?
|
| Vascular Diseases | 1 | 2015 | 75 | 0.030 |
Why?
|
| Tumor Burden | 1 | 2014 | 59 | 0.030 |
Why?
|
| DNA Methylation | 1 | 2016 | 271 | 0.030 |
Why?
|
| Case-Control Studies | 1 | 2017 | 1051 | 0.030 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 1 | 2014 | 55 | 0.030 |
Why?
|
| Breast | 1 | 2015 | 173 | 0.030 |
Why?
|
| Real-Time Polymerase Chain Reaction | 1 | 2014 | 191 | 0.030 |
Why?
|
| Azacitidine | 1 | 2013 | 13 | 0.030 |
Why?
|
| Mice, Knockout | 1 | 2018 | 1994 | 0.030 |
Why?
|
| Antimetabolites, Antineoplastic | 1 | 2013 | 39 | 0.030 |
Why?
|
| Immunophenotyping | 1 | 2013 | 184 | 0.030 |
Why?
|
| RNA, Messenger | 2 | 2008 | 1465 | 0.030 |
Why?
|
| Receptor, ErbB-2 | 1 | 2012 | 51 | 0.020 |
Why?
|
| Electrons | 1 | 2012 | 34 | 0.020 |
Why?
|
| Receptors, Interleukin-1 | 1 | 2012 | 66 | 0.020 |
Why?
|
| Nestin | 1 | 2011 | 13 | 0.020 |
Why?
|
| Prognosis | 1 | 2016 | 1600 | 0.020 |
Why?
|
| Transfection | 1 | 2014 | 675 | 0.020 |
Why?
|
| Intermediate Filament Proteins | 1 | 2011 | 19 | 0.020 |
Why?
|
| Clusterin | 1 | 2011 | 4 | 0.020 |
Why?
|
| SOXE Transcription Factors | 1 | 2011 | 6 | 0.020 |
Why?
|
| ErbB Receptors | 1 | 2012 | 114 | 0.020 |
Why?
|
| Proto-Oncogene Proteins c-kit | 1 | 2011 | 31 | 0.020 |
Why?
|
| Infant | 1 | 2016 | 1486 | 0.020 |
Why?
|
| Boston | 1 | 2011 | 246 | 0.020 |
Why?
|
| Cohort Studies | 1 | 2016 | 2374 | 0.020 |
Why?
|
| Indonesia | 1 | 2010 | 18 | 0.020 |
Why?
|
| Lichenoid Eruptions | 1 | 2009 | 2 | 0.020 |
Why?
|
| Papillomaviridae | 1 | 2010 | 58 | 0.020 |
Why?
|
| Infant, Newborn | 1 | 2014 | 1283 | 0.020 |
Why?
|
| Leukoencephalopathy, Progressive Multifocal | 1 | 2009 | 18 | 0.020 |
Why?
|
| Acne Vulgaris | 1 | 2009 | 23 | 0.020 |
Why?
|
| Antibodies, Monoclonal, Murine-Derived | 1 | 2009 | 57 | 0.020 |
Why?
|
| Pruritus | 1 | 2009 | 29 | 0.020 |
Why?
|
| Rituximab | 1 | 2009 | 80 | 0.020 |
Why?
|
| Triamcinolone | 1 | 2009 | 2 | 0.020 |
Why?
|
| Prospective Studies | 1 | 2016 | 3067 | 0.020 |
Why?
|
| Injections, Intralesional | 1 | 2009 | 12 | 0.020 |
Why?
|
| Erythema Multiforme | 1 | 2008 | 1 | 0.020 |
Why?
|
| Rats, Transgenic | 1 | 2008 | 7 | 0.020 |
Why?
|
| tat Gene Products, Human Immunodeficiency Virus | 1 | 2008 | 13 | 0.020 |
Why?
|
| Histamine Release | 1 | 2008 | 3 | 0.020 |
Why?
|
| Basophils | 1 | 2008 | 14 | 0.020 |
Why?
|
| Skin Tests | 1 | 2008 | 21 | 0.020 |
Why?
|
| Skin Ulcer | 1 | 2008 | 14 | 0.020 |
Why?
|
| Rare Diseases | 1 | 2009 | 38 | 0.020 |
Why?
|
| Hyperplasia | 1 | 2008 | 84 | 0.020 |
Why?
|
| Injections, Subcutaneous | 1 | 2008 | 69 | 0.020 |
Why?
|
| Antigens, CD1d | 1 | 2008 | 28 | 0.020 |
Why?
|
| Enterobacter | 1 | 2008 | 5 | 0.020 |
Why?
|
| Leukocytes | 1 | 2008 | 97 | 0.020 |
Why?
|
| Immunization | 1 | 2008 | 128 | 0.020 |
Why?
|
| Streptococcus | 1 | 2008 | 17 | 0.020 |
Why?
|
| Methicillin Resistance | 1 | 2008 | 21 | 0.020 |
Why?
|
| Genes, Dominant | 1 | 2008 | 55 | 0.020 |
Why?
|
| Leg Dermatoses | 1 | 2007 | 3 | 0.020 |
Why?
|
| HIV Envelope Protein gp120 | 1 | 2008 | 130 | 0.020 |
Why?
|
| HIV Antibodies | 1 | 2008 | 133 | 0.020 |
Why?
|
| Age of Onset | 1 | 2008 | 170 | 0.020 |
Why?
|
| Surgical Procedures, Operative | 1 | 2009 | 137 | 0.020 |
Why?
|
| Enzyme Activation | 1 | 2008 | 359 | 0.020 |
Why?
|
| Photomicrography | 1 | 2006 | 2 | 0.020 |
Why?
|
| Killer Cells, Natural | 1 | 2008 | 218 | 0.020 |
Why?
|
| Staphylococcus aureus | 1 | 2008 | 169 | 0.020 |
Why?
|
| Intradermal Tests | 1 | 2006 | 3 | 0.020 |
Why?
|
| Receptors, Antigen, T-Cell | 1 | 2008 | 281 | 0.020 |
Why?
|
| Patch Tests | 1 | 2006 | 11 | 0.020 |
Why?
|
| Contraceptives, Oral | 1 | 2006 | 22 | 0.020 |
Why?
|
| Menstrual Cycle | 1 | 2006 | 81 | 0.020 |
Why?
|
| Leukemic Infiltration | 1 | 2004 | 5 | 0.010 |
Why?
|
| Rats | 1 | 2008 | 1910 | 0.010 |
Why?
|
| Clone Cells | 1 | 2004 | 106 | 0.010 |
Why?
|
| Cytokines | 1 | 2008 | 912 | 0.010 |
Why?
|
| Practice Guidelines as Topic | 1 | 2009 | 705 | 0.010 |
Why?
|
| Cell Line | 1 | 2008 | 1984 | 0.010 |
Why?
|
| Algorithms | 1 | 2009 | 976 | 0.010 |
Why?
|
| Cells, Cultured | 1 | 2008 | 2093 | 0.010 |
Why?
|
| Sensitivity and Specificity | 1 | 2006 | 1093 | 0.010 |
Why?
|
| Capillaries | 1 | 2002 | 30 | 0.010 |
Why?
|
| Syndrome | 1 | 2002 | 170 | 0.010 |
Why?
|
| Antibody Formation | 1 | 2002 | 108 | 0.010 |
Why?
|
| Fluorescent Antibody Technique | 1 | 2002 | 217 | 0.010 |
Why?
|
| Transplantation, Homologous | 1 | 2002 | 244 | 0.010 |
Why?
|
| Endothelium, Vascular | 1 | 2002 | 169 | 0.010 |
Why?
|
| Tongue | 1 | 2000 | 15 | 0.010 |
Why?
|
| Cardiovascular Diseases | 1 | 2008 | 788 | 0.010 |
Why?
|
| Polysomnography | 1 | 2000 | 55 | 0.010 |
Why?
|
| T-Lymphocytes | 1 | 2004 | 986 | 0.010 |
Why?
|
| Risk Assessment | 1 | 2006 | 1921 | 0.010 |
Why?
|
| Lung | 1 | 2002 | 919 | 0.010 |
Why?
|